Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Gains from Sales and Divestitures (2017 - 2022)

Arcus Biosciences (RCUS) has 6 years of Gains from Sales and Divestitures data on record, last reported at $500000.0 in Q4 2022.

  • For Q4 2022, Gains from Sales and Divestitures rose 30.83% year-over-year to $500000.0; the TTM value through Dec 2022 reached $500000.0, up 30.83%, while the annual FY2022 figure was $500000.0, 30.83% up from the prior year.
  • Gains from Sales and Divestitures reached $500000.0 in Q4 2022 per RCUS's latest filing, up from $382183.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $500000.0 in Q4 2022 and bottomed at $6250.0 in Q4 2020.
  • Average Gains from Sales and Divestitures over 5 years is $255225.0, with a median of $372774.0 recorded in 2019.
  • Peak YoY movement for Gains from Sales and Divestitures: plummeted 98.32% in 2020, then soared 6014.93% in 2021.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $14918.0 in 2018, then surged by 2398.82% to $372774.0 in 2019, then tumbled by 98.32% to $6250.0 in 2020, then skyrocketed by 6014.93% to $382183.0 in 2021, then soared by 30.83% to $500000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $500000.0 in Q4 2022, $382183.0 in Q4 2021, and $6250.0 in Q4 2020.